C-AQQMSenisca
RNA splicing, senotherapeutics, oligonucleotides
modulatingrna therapeutic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-AQQM
C-AQQMC-AQQMRNA splicing, senotherapeutics, oligonucleotides
0-100 chain-logic scale · 15 dimensions · scored on public evidence
SENISCA states that ageing and age-related disease are driven in major part by the accumulation of senescent cells and by a loss of cells' ability to finely tune gene expression through alternative splicing. The company says ageing alters splicing factor levels, reducing molecular resilience and causing cells to become senescent, and it argues that restoring youthful splicing factor levels can reverse senescence, rejuvenate aged cells, and help treat both diseases and aesthetic signs of ageing through oligonucleotide-based interventions.
SourceSenisca states that cellular ageing can be reversed by restoring cells’ ability to fine tune gene expression, specifically through modulation of RNA splicing and recovery of splicing factor levels seen in younger cells. It presents senescent cell accumulation as a major cause of age-related disease and aesthetic ageing, and claims its oligonucleotide-based senotherapeutic approach can rejuvenate old cells and help target both diseases and visible signs of ageing.
SourceSENISCA states that ageing-related disease and visible ageing are driven in major part by the accumulation of senescent cells, and that these cells can be rejuvenated rather than only removed. The company says cellular ageing happens because ageing disrupts splicing-factor levels and weakens cells’ ability to fine tune gene expression, and it believes restoring youthful splicing-factor function can reverse senescence and enable a new class of oligonucleotide-based therapies for diseases and aesthetic signs of ageing.
SourceSENISCA states that cellular ageing and many age-related diseases and aesthetic signs of ageing are driven in part by the accumulation of senescent cells and by age-related loss of cells’ ability to finely tune gene expression. The company says this decline is caused by changes in splicing factor levels during ageing, and that restoring more youthful splicing factor activity can reverse senescence, rejuvenate aged cells, and turn back the ageing clock through oligonucleotide-based senotherapeutic interventions.
Source